uMed

uMed is a healthcare technology company that accelerates medical research by building consented patient cohorts and generating real-time clinical data insights. Its flagship offering, the ACCESS Research Platform, enables rapid identification and engagement of patients for decentralized registries such as AccessCMD in cardiometabolic disease. The company partners with healthcare institutions to facilitate ethical recruitment, consent management, and collection of electronic health records, genetic tests, wearable device data, biosamples, and patient-reported outcomes for use in life science research. As of July 2024, their AccessCMD Cardiometabolic Cohort enrolled over 2,000 participants within four months.